Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMLYGIC in stage IIIc and IV malignant melanoma
NCT02574260Phase 2Completed
- Sponsor
- BioVex Group, Inc.
- Start
- Aug 2008
- Primary completion
- Jan 2010
01
Overview
Phase 2, open-label, single-arm trial of talimogene laherparepvec in melanoma, sponsored by BioVex Group, Inc. Primary endpoint: Adverse Events. Started Aug 2008; status: completed.
02
Drugs
talimogene laherparepvec
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT02574260.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02574260.